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Reduced glutathione as a physiological
co-activator in the activation of
peptidylarginine deiminase
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Abstract
Background: Citrullination catalysed by peptidylarginine deiminases (PADs) plays an important pathogenic role in
anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) and, possibly, several other inflammatory
diseases. Non-physiological reducing agents such as dithiothreitol (DTT) are normally added to the reaction buffer
when determining PAD activity in vitro. We investigated the ability of reduced glutathione (GSH), the most
abundant intracellular small-molecule thiol in vivo, to activate PADs.
Methods: Activity of recombinant human (rh) PAD2 and PAD4, PADs contained in synovial fluid (SF) samples from
RA patients and PADs released from phorbol 12-myristate 13-acetate (PMA)-stimulated cells was measured using an
in-house PAD activity assay detecting citrullination of fibrinogen.
Results: No activity of rhPAD2, rhPAD4 or PADs within SF was observed without addition of an exogenous reducing
agent. Activity of both recombinant and SF PAD was observed in the presence of 1 mM DTT or 10–15 mM GSH.
Following stimulation with PMA, human isolated leucocytes, but not mononuclear cells, released enzymatically active
PAD, the activity of which was abolished upon pre-incubation of the cells with the glutathione reductase
inhibitor 2-AAPA. No PAD activity was observed in the corresponding supernatants, but addition of exogenous
GSH restored activity.
Conclusions: Catalytic activity of PAD requires reducing conditions. GSH meets this requirement at concentrations
comparable with those found within cells. Active PAD, reduced by GSH, is released from PMA-stimulated granulocytes,
but becomes inactivated in the extracellular space.
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Background
Citrullination refers to the post-translational conversion
of protein arginine residues into citrulline residues, a
process catalysed by peptidylarginine deiminases (PADs)
1–4 and PAD6 [1]. Citrullination plays an important
pathogenic role in anti-citrullinated protein antibody
(ACPA)-positive rheumatoid arthritis (RA) [2, 3] and,
possibly, in a number of other autoimmune diseases,
inflammatory diseases or neurodegenerative conditions,
including multiple sclerosis [4], Alzheimer’s disease [5],
psoriasis [6], Sjögren’s syndrome [7], type 1 diabetes [8]
and chronic obstructive pulmonary disease [9].
Most studies on PAD activity and functional studies of
citrullinated proteins have been based on in vitro
citrullination using the reducing agent dithiothreitol
(DTT) and exogenously added calcium. The calcium
dependency of PADs is well described: upon binding of
calcium, Cys645 in PAD4 (Cys647 in PAD2) translocates
into a position in the catalytic site, where nucleophilic
attack on guanidinium groups of target arginines takes
place [10, 11]. The PAD requirement for calcium is met
in the extracellular space [12] and, under certain circum-
stances, also intracellularly [13]. The dependency of
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PADs on reducing agents is less well understood.
Reduction of the active site thiol Cys645/647 is likely to
precede attack on the guanidinum carbon of arginine.
Thus, the redox balance might be an additional regulator
for PAD’s catalytic activity. While DTT is a non-
physiological synthetic molecule, reduced glutathione
(GSH) is a physiological reducing agent that may
facilitate PAD activity in vivo. GSH is a linear tripeptide
of L-glutamine, L-cysteine and glycine, and contains a
sulfhydryl (SH) group on the cysteinyl portion, account-
ing for its strong electron-donating character. GSH is
the most abundant intracellular small-molecule thiol,
and is essential for maintaining the thiol status of vari-
ous molecules. GSH has many biological roles, including
protection against reactive oxygen and nitrogen species
(ROS/NOS), which are reduced by two GSH molecules
forming oxidized glutathione (GSSG) in the process [14].
GSH has been demonstrated in cytosol and in organelles
of virtually all cells of the body at the low millimolar
range [15], whereas extracellular levels are two to three
orders of magnitude lower [16, 17].
Owing to involvement in many cellular functions, it is
not surprising that dysregulation of GSH has been asso-
ciated with various diseases [14]. The glutathione reduc-
tase, which converts GSSG to GSH, has been found
upregulated in synovial fluid (SF) from RA patients [18],
and blood from RA patients contains higher levels of
GSH, as well as higher GSH:GSSG ratios, than blood
from healthy controls [19].
We hypothesize that, in addition to calcium, reducing
agents are required for PADs to become enzymatically
active, and that GSH is the major physiological reducing
agent in this respect.
Using an assay for citrullination of matrix-bound
fibrinogen, we here analyse the impact of GSH on re-
combinant human PADs (rhPADs), on PADs contained
in SF and on PADs released from stimulated human
leucocytes.
Methods
Cells, serum and SF
Blood samples were obtained from healthy donors
attending the Blood Bank at Copenhagen University
Hospital, Rigshospitalet, Denmark. All donors were
anonymous to the investigators.
One hour after collection, serum was isolated from
venous blood drawn into 10 ml dry Vacutainer tubes
(BD Bioscience, Brøndby, Denmark) by centrifugation at
400 × g for 10 min at 20 °C. Pooled serum from blood
group AB-positive donors, henceforward referred to
as “AB serum”, was purchased from Sigma-Aldrich
(St. Louis, MO, USA).
Cells were isolated from venous blood drawn into 10 ml
lithium-heparin tubes (BD Bioscience). Blood leucocytes
were isolated after lysis of erythrocytes in heparinized
blood by incubation with ammonium chloride (In Vitro
As, Fredensborg, Denmark) for 7 min. Mononuclear cells
(MNCs) were isolated by gradient centrifugation of
heparinized blood using LymphoPrep™ (Axis-Shield, Oslo,
Norway). Before use, both cell preparations were washed
twice in RPMI 1640, 25 mM Hepes containing 0.42 mM
calcium nitrate, L-glutamine and gentamicin (In Vitro As).
SF samples from nine ACPA-positive RA patients,
fulfilling the American College of Rheumatology 1987
diagnostic criteria [20], were obtained from Dr Ladislav
Senolt, Charles University in Prague, Czech Republic.
The study was approved by the Ethics Committee of the
Institute of Rheumatology and written informed con-
sents were obtained from all patients prior to initiation
of the study. Samples were centrifuged at 1900 × g for 10
min to remove cells and were stored at –80 °C prior to
analysis.
Reagents
rhPAD2 and rhPAD4 were produced, purified and de-
fined by means of mass concentration, as described
previously [21]. GSH was purchased from Sigma-Aldrich.
The glutathione reductase inhibitor (GRI) 2-acetylamino-3-
[4-(2-acetylamino-2-carboxyethylsulfanylthiocarbonyla-
mino)phenylthiocarbamoylsulfanyl]propionic acid hy-
drate (2-AAPA) was purchased from Sigma-Aldrich.
Monoclonal mouse anti-citrullinated fibrinogen (clone
20B2; catalogue number MQ13.102) was purchased
from ModiQuest (Oss, Netherlands).
Cell-free assay for PAD activity
Maxisorp plates (Nunc, Roskilde, Denmark) were coated
overnight at 4 °C with 100 μl/well of 1.0 μg/ml fibrino-
gen (Calbiochem, Darmstadt, Germany) in coating buffer
(30 mM Na2CO3, 70 mM NaHCO3, pH 9.6). Wells were
washed three times and blocked in Tris-buffered saline
(TBS) buffer containing 0.05 % Tween-20, pH 7.4, for 20
min at room temperature (RT). Next, the wells were in-
cubated (100 μl/well for 180 min at RT) with: rhPAD2
and/or rhPAD4 (300 ng/ml in 100 mM Tris–HCl, pH
7.5); SF (undiluted 50 μl; diluted 1:2 in 100 mM Tris–
HCl, pH 7.5); serum (diluted 1:2 in 100 mM Tris–HCl,
pH 7.5); or cell culture supernatants (diluted 1:1 in 100
mM Tris–HCl, 10 mM CaCl2, pH 7.5). The reactions
took place in the presence of various combinations of
rhPAD2/4, DTT (1 mM), EDTA (25 mM) or GSH and
CaCl2 at various concentrations, as specified in the figure
legends. After three washes in washing buffer (PBS, 0.05 %
Tween-20, pH 7.4), murine anti-citrullinated fibrinogen
antibody (0.5 μg/ml) was incubated for 90 min at RT.
After three further washes, wells were incubated with
100 μl horseradish peroxidase-conjugated polyclonal
rabbit-anti mouse immunoglobulin antibodies (P0260;
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Dako, Glostrup, Denmark) diluted 1:1000 in washing
buffer. Finally, the plates were washed three times in
washing buffer and incubated with 0.4 mg/ml o-phe-
nylene-diamine (Kem-En-Tec, Taastrup, Denmark) in
developing buffer (35 mM citric acid, 65 mM
Na2PO4, pH 5.0). After 10 min, the colour reaction
was stopped with 1.0 M H2SO4, and the optical dens-
ity (OD) was measured at 490–650 nm using the
SPECTROstar nano Microplate Reader (BMG Lab-
tech, Ortenberg, Germany). Data were processed
using MARS software (BMG Labtech).
Assay for cell-mediated PAD activity
Isolated leucocytes or MNCs were added to microtitre
wells coated with fibrinogen, washed and blocked as
already described, and incubated for 180 min under agi-
tation at RT. Purified cells were diluted 1:1 with RPMI
1640 to a final concentration of 5 % AB serum and,
when relevant, 15 nM phorbol 12-myristate 13-acetate
(PMA) and 50 μM 2-AAPA (which were incubated for
20 min with cells prior to stimulation). Cells were
removed by washing four times in PBS and 0.05 %
Tween-20, and plates were developed as already described.
PAD2 measurement
PAD2 was measured using an in-house ELISA, as de-
scribed previously [22]. SF was diluted 1:10 as described
in [23] and cell supernatants were diluted 1:1 with PBS
containing 0.05 % Tween-20, pH 7.4.
Results
Reduction of PADs is a prerequisite for enzyme activity
PAD activity was determined in microtitre plates con-
taining immobilized human fibrinogen, using an
antibody specifically reactive with citrullinated fibrino-
gen. In the presence of DTT (1 mM in Tris–HCl buffer
containing 10 mM CaCl2) as a reducing agent, we ob-
served ample citrullination of human fibrinogen by
rhPAD2 and/or rhPAD4 (Fig. 1a). No citrullination was
observed when a pool of SF from four RA patients was
used, although we have previously shown that SF con-
tained PAD2 and 1.5–2.5 mM calcium [12, 23]. The
addition of rhPAD2 and rhPAD4 to SF did not result in
detectable fibrinogen citrullination, except when DTT
was also present. A similar pattern was observed for a
pool of sera from five healthy donors.
GSH-mediated reduction can activate PADs
To investigate whether GSH could substitute for DTT as
a reducing agent, we examined the enzymatic activity of
rhPAD2 and rhPAD4 over a range of GSH concentra-
tions and at a fixed CaCl2 concentration of 10 mM
(Fig. 1b). Catalytic activity required GSH concentrations
above 1 mM, reached a peak around 10–15 mM and de-
clined with further increasing GSH concentrations. At
GSH concentrations above 25 mM, no PAD activity was
observed. In contrast, the activity of both rhPAD iso-
forms reached a plateau at DTT concentrations between
1 mM and 50 mM (data not shown). As shown previ-
ously with DTT as a reducing agent [12], PAD2 showed
higher efficacy than PAD4 in the employed assay
(Fig. 1b).
Calcium is required for GSH-mediated PAD activity
As expected, the catalytic activity of both rhPAD2 and
rhPAD4 was calcium dependent, irrespective of whether
GSH or DTT was used as a reducing agent (Fig. 2).
Higher calcium concentrations were required to obtain
Fig. 1 Requirements of PAD for reducing agents. a Microtitre plates coated with human fibrinogen were incubated for 3 h at RT with CaCl2-containing
buffer alone, a pool of synovial fluid (SF) from four patients with RA (33 % v/v in buffer) or a pool of serum from five healthy donors (33 % v/v in
buffer). rhPAD2 and rhPAD4, mixed at a molar ratio of 1:1, and 1 mM dithiothreitol (DTT) were added as indicated. The catalytic activity of rhPADs was
measured by an ELISA detecting citrullination of fibrinogen by means of the mAb 20B2, and is expressed as optical density (OD). b Individual activities
of rhPAD2 and rhPAD4 at various concentrations of reduced glutathione (GSH) in buffer containing 10 mM CaCl2. All data represent the mean and
range of duplicate measurements. rhPAD recombinant human peptidylarginine deiminase
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half-maximal activities in the presence of GSH than in
the presence of DTT; 0.69 mM versus 0.32 mM CaCl2,
respectively, for PAD2, and 0.62 mM versus 0.26 mM
CaCl2, respectively, for PAD4. The activity of rhPADs in
Tris–HCl buffer containing 10 mM CaCl2 was around
8-fold lower in the presence of 10 mM GSH than in the
presence of 1 mM DTT (data not shown).
PAD activity in SF is dependent on reducing conditions
To examine the PAD-reducing capacity of GSH in a
physiologically relevant setting, we examined the cata-
lytic activity of native PAD enzymes contained in a pool
of SF from five RA patients in the presence and absence
of GSH. ELISA verified that the pool contained PAD, the
concentration of PAD2 being 18 ng/ml. As shown in
Fig. 3, pure SF as well as SF supplemented with 10 mM
CaCl2 failed to exhibit catalytic activity above that ob-
served in negative controls containing the calcium chela-
tor EDTA, which blocks PAD activity. However, when
SF was supplemented with 10 mM GSH in the presence
or absence of exogenously added CaCl2, substantial
citrullination was observed.
Enzymatic activity of PAD released from stimulated
leucocytes
To examine whether PAD released from cells is catalyt-
ically active, we cultivated blood leucocyte cells in
microwells coated with fibrinogen to allow citrullination
in situ (Fig. 4a). No catalytic activity was observed in wells
containing unstimulated cells, but stimulation of the leu-
cocytes with PMA resulted in substantial citrullination of
fibrinogen (Fig. 4a, grey columns). As expected, this signal
could be inhibited by EDTA. Addition of exogenous
rhPAD2 did not further increase the catalytic activity in
the wells, which was tested in experiments involving leu-
cocytes from 10 different donors (Fig. 4b), indicating that
the requirements for PAD activity were not met in the
medium. Addition of DTT enhanced activity of the re-
leased PAD and rendered the exogenously added rhPAD2
active (Fig. 4b). Taken together, these data suggest that
stimulation of leucocytes by PMA leads to the release of
PAD, which is temporarily enzymatically active and loses
its activity in the oxidative environment.
In contrast with total leucocytes, purified MNCs did
not show PAD activity upon stimulation (Fig. 4c), sug-
gesting that granulocytes were the main providers of
catalytically active PAD (Fig. 4a). In agreement with the
finding that exogenous rhPAD2 did not enhance the
catalytic activity in wells containing PMA-stimulated
cells, rhPAD2 added to supernatants from the unstimu-
lated or PMA-stimulated cells was not enzymatically ac-
tive unless supplemented with GSH (data not shown).
The highest activity was observed at GSH concentra-
tions around 20–25 mM, and no activity was observed
at a concentration of 50 mM (data not shown).
To determine whether PADs released from stimulated
leucocytes (Fig. 4a) had gained catalytic activity through re-
duction by endogenous GSH, we stimulated leucocytes
with PMA in the presence of a selective GRI (2-AAPA)
[24] (Fig. 5a). Inclusion of the GRI abrogated enzymatic
Fig. 2 Calcium dependency of PAD reduced by glutathione. Microtitre
plates were coated with human fibrinogen and incubated for 3 h at
RT with rhPAD2 (300 ng/ml) or rhPAD4 (3000 ng/ml) and either 1 mM
dithiothreitol (DTT) (open symbols) or 10 mM reduced glutathione (GSH)
(closed symbols) in the presence of CaCl2 at concentrations ranging
from 20 μM to 10 mM. Citrullination of fibrinogen was measured using
mAb 20B2 as the detecting antibody. Activity of PAD is shown as the
percent of maximal activity for each enzyme, expressed as the mean
and range of duplicate measurements. rhPAD recombinant human
peptidylarginine deiminase
Fig. 3 Reduced glutathione (GSH) induces PAD activity in synovial
fluid (SF). Microtitre plates were coated with human fibrinogen and
incubated for 3 h at RT with a pool of SF from five RA patients
supplemented with different combinations of CaCl2 (10 mM), GSH
(10 mM) or EDTA (25 mM). Citrullination of fibrinogen was measured
using mAb 20B2 as the detecting antibody. Bars and error bars
represent the mean and SEM of triplicate measurements
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activity signals to those observed in the presence of EDTA.
Importantly, GRI did not prevent PAD from being released.
Thus, inclusion of GRI diminished neither the PAD2
concentration (Fig. 5b) nor the PAD activity (Fig. 5c) of the
supernatants. No activity was observed in supernatants
without exogenously added GSH (data not shown).
Discussion
The physiological agent(s) responsible for reducing PADs
to their physiologically active state have not been
identified. In general, PAD activity studies in vitro have
used DTT or a related compound not present in nature as
a reducing agent. Thus, enzymatic activity of PADs con-
tained in SF [12, 23], in cell lysates [25] or released by cells
[26, 27] has generally not been examined under physio-
logical conditions, because DTT has been included in the
experiments. We hypothesized that GSH is a natural redu-
cing agent required for PADs to be enzymatically active.
Indeed, enzymatic activity of rhPAD2 and rhPAD4 was
observed at GSH concentrations corresponding to those
Fig. 4 Release of catalytically active peptidylarginine deiminase (PAD) from PMA-stimulated granulocytes. a Microtitre plates coated with human
fibrinogen were incubated for 3 h at RT with blood leucocytes resuspended in RPMI medium containing 5 % normal human serum with or
without 25 mM EDTA. Cells were stimulated with PMA (15 nM) and subsequent citrullination of fibrinogen was measured using mAb 20B2 as the
detecting antibody. Average and upper range of duplicate optical density (OD) measurements shown for three donors. b Enzymatic activity of
PMA-stimulated leucocytes from 10 individual donors was examined in a similar manner in the presence and absence of exogenous rhPAD2
(300 ng/ml) and/or 1 mM dithiothreitol (DTT). Shown are averages of duplicate measurements after subtraction of background values obtained in
the presence of EDTA. c Using the same procedure, mononuclear cells (MNCs) from donor 1 in a were assessed. Average and upper range of
duplicate OD measurements are shown. PMA phorbol 12-myristate 13-acetate
Fig. 5 Effect of glutathione reductase inhibition on the catalytic activity of peptidylarginine deiminase (PAD) released from cells. a Microtitre
plates coated with human fibrinogen were incubated for 3 h at RT with leucocytes isolated from three healthy donors in media without PMA,
media with 15 nM PMA alone or media with 15 nM PMA in combination with 50 μM of the glutathione reductase inhibitor (GRI) 2-AAPA. Citrullination
of fibrinogen was detected using mAb 20B2 and optical density (OD) values are shown as the average and upper range of triplicate measurements.
b PAD2 concentration in cell supernatants is shown as the average and upper range of duplicate measurements. c Catalytic activity of PAD in cell
supernatants supplemented with 5 mM CaCl2 and 25 mM of reduced glutathione (GSH) shown as the average and upper range of duplicate OD
measurements using mAb 20B2 as a detector of citrullinated fibrinogen. PMA phorbol 12-myristate 13-acetate
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found in cytosol (i.e. around 4.5 mM) [15]. To our
knowledge, intracellular GSH levels exceeding 15 mM
have not been observed in vivo, and therefore the dimin-
ished PAD activity observed at high concentrations of
exogenously added GSH in this study may not be
physiologically relevant.
We did not observe any PAD activity in pooled SF
from RA patients without addition of GSH or DTT.
Spengler et al. [27] recently reported weak PAD activity
in pure, freshly obtained SF from untreated RA patients,
which was higher than in SF from OA patients, albeit
100-fold lower than the activity in the presence of DTT-
containing citrullination buffer. The differences between
their observations and ours may rely on their use of a
different assay for protein citrullination and, possibly,
usage of freshly isolated SFs. The low or absent PAD ac-
tivity in SF observed here and by others [27] suggests
that an essential factor was missing for PADs to function
optimally. Our finding that addition of DTT or GSH to
SF strongly enhanced PAD activity indicates that a redu-
cing agent(s) is this essential factor.
Circulating proteins produced outside joints (e.g.
fibrinogen produced in the liver) are present in a
citrullinated form in SF from RA patients [28, 29],
suggesting that extracellular citrullination occurs within
the joints, where the calcium concentration is sufficiently
high for PADs to be active. Our finding that PMA-
stimulated leucocytes cultured in microtitre wells were
capable of citrullinating fibrinogen coated in wells
suggests that the leucocytes either released PAD in
reduced form or co-released substance(s) capable of
reducing PAD.
Evidence for GSH being critical for reduction of PAD
came from the finding that citrullination was abrogated
by addition of the highly specific GRI 2-AAPA [24] to
cells before incubation in the wells. Extracellular leuco-
cyte PAD most probably originates from granulocytes,
because PMA-stimulated MNCs devoid of granulocytes
were not capable of citrullinating fibrinogen. The
presence of PAD2 and of PAD activity (after addition
of GSH) in supernatants from the cultures exposed to
2-AAPA suggested that 2-AAPA did not inhibit PAD
release. However, we cannot rule out that 2-AAPA
has effects on PAD activity other than that caused by
enhancement of the GSSG:GSH ratio. The enzymatic
activity of the supernatants was low compared with
the activity observed in the presence of cells, suggest-
ing that citrullination of fibrinogen took place in the
close vicinity of the cells, where high local concentra-
tions of reduced PADs could be obtained. It is likely
that PADs are rapidly oxidized, and thereby inacti-
vated, upon release from granulocytes.
With respect to citrullination of intracellular proteins,
the PAD requirement for GSH is clearly met intracellularly
[15]. Indeed, intracellularly located citrullinated proteins
have been observed in the synovium of RA patients, indi-
cating that calcium concentrations high enough for PADs
to be active can be reached intracellularly under certain
circumstances [13]. Accordingly, PAD enzymes are known
to modulate gene expression [30–32]. It is noteworthy
that GSH can also be recruited to the nucleus (e.g.
during the early phase of cell proliferation [33]) and
is also involved in gene expression [34, 35].
A limitation of this study is that we cannot distinguish
between PAD2 and PAD4 activity. Granulocytes are
known to release both isoforms upon PMA stimulation
[26, 27]. We have shown previously that ~150-fold more
rhPAD4 than rhPAD2 is required to citrullinate the epi-
tope recognized by the detecting antibody in the assay
used in this study [12], and thus it can be speculated
that PAD2 is primarily responsible for the citrullination
observed. We cannot exclude an influence of other
physiological reducing agents on PAD activation in
vivo. Indeed, thioredoxin has been reported to be 5-
fold increased in SF of RA patients compared with
OA patients [36]. However, the complete abrogation
of cell-mediated citrullination by blockade of gluta-
thione reductase suggests that GSH is predominantly
responsible for reduction of PAD under normal phy-
siological conditions.
Conclusion
This study shows for the first time that the physiological
reducing agent GSH, at concentrations similar to those
present in cytosol, is capable of reducing PADs to a
degree that suffices for citrullination to occur. We found
that the thiol status of PADs is as important as binding
of calcium for PAD’s catalytic activity.
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